1. Medtech Insight
  2. >>Policy & Regulation

UK On Cusp Of Value-Based Procurement With NHS Future Operating Model Going Live

 
• By Ashley Yeo

The UK's complex system of procuring medical technology for use in the National Health Service is being simplified. A new system will go live on May 8 under the Future Operating Model (FOM), an initiative that prioritizes outcomes-based rationales and allows for gain-sharing, while also targeting annual NHS savings. At this early stage, the device industry and health-care providers are both displaying a mix of optimism and skepticism.

uk pound coins and uk flag

The UK's National Health Service Supply Chain contract ended andproposals from a government reviewto reduce cost variation in NHS England's secondary care setting signaled a need to rethink the complex and costly NHS procurement methods for medical technology. The plan that emerged, the Future Operating Model, is designed to save NHS money annually, but not in the transactional sense. Instead, it deploys value-based health-care concepts that are designed to yield sustainable benefits for patients, as well as the payer and provider. Also see "UK Outlook 2018: Medtech Readies For Change To FOM System Of Value-Based Procurement" - Medtech Insight, 8 February, 2018.

FOM was the focus of an event hosted by the Association of British Healthcare Industries, the UK medtech industry association, in London on March 20. It was, as ABHI Chief...

Rationalization And Simplification Of NHS Procurement: A No-Brainer

The case for simplification of NHS procurement is made easily. There are 320,000 products in the Supply Chain catalog, yet the average Trust uses just over 9,000 of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

First AI Breast Cancer Prediction Platform Receives FDA Authorization

 
• By Natasha Barrow

Clairity’s "first-in-class" mammography-based AI screening tool, Clairity Breast, provides "equitable risk assessments," expanding access to lifesaving early detection for breast cancer, said company founder Connie Lehman.

Final Curtain For LDTs? FDA Will Not Appeal District Court Decision To Vacate Final Rule

 
• By Brian Bossetta

The US FDA has given up on its effort to regulate lab-developed tests as medical devices, at least for now. The agency will not appeal a decision from the Eastern District of Texas that tossed out the FDA’s final rule, leaving the agency with few cards.

Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System

 
• By Marion Webb

Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 
• By Brian Bossetta

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.

More from Medtech Insight

Siemens Healthineers Widens FY25 EPS Range By €0.15 To Absorb Up To €300M In Tariff Costs

 
• By Shubham Singh

The imaging, Varian, and advanced therapies segments – which are more reliant on equipment sales – are more heavily affected, with tariffs applying to roughly 55% of their revenue base. In diagnostics, the company expects minimal exposure due to sufficient US value-added manufacturing.

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 
• By Brian Bossetta

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By Marion Webb

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.